Related Experiment Video

Updated: Jun 20, 2026

A General Method for Evaluating Deep Brain Stimulation Effects on Intravenous Methamphetamine Self-Administration
09:16

A General Method for Evaluating Deep Brain Stimulation Effects on Intravenous Methamphetamine Self-Administration

Published on: January 22, 2016

Less common side effects of methyldopa

W Chan

    The Medical Journal of Australia
    |July 2, 1977
    PubMed

    Insights

    Methyldopa can cause severe side effects like hyperpyrexia, antinuclear factors, and ocular issues. These adverse effects resolve upon discontinuing methyldopa, with safer alternatives available.

    Area of Science:

    • Pharmacology
    • Internal Medicine
    • Toxicology

    Background:

    • Methyldopa is an antihypertensive medication.
    • Drug-induced adverse effects require careful monitoring.

    Observation:

    • A case of methyldopa-induced hyperpyrexia is presented.
    • Associated symptoms included positive antinuclear factors, LE cells, and ocular disturbance.

    Findings:

    • All observed side effects resolved after discontinuing methyldopa.
    • The incidence of these specific adverse reactions to methyldopa is reviewed.

    Implications:

    • Clinicians should be aware of potential methyldopa-induced autoimmune phenomena and hyperpyrexia.
    • Discontinuation of methyldopa is recommended if these side effects manifest.
    • Alternative antihypertensive agents with better safety profiles are available.

    More Related Videos

    Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease06:45

    Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

    Published on: October 4, 2021

    Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease05:51

    Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

    Published on: October 14, 2021

    Related Concept Videos

    Adrenergic Agonists: Mixed-Action Agents01:28

    Adrenergic Agonists: Mixed-Action Agents

    Mixed-action adrenergic agonists, like ephedrine and pseudoephedrine, directly and indirectly affect adrenergic receptors. These agents stimulate adrenoceptors and indirectly release stored neurotransmitters, amplifying the adrenergic response.
    Ephedrine and pseudoephedrine lack a catecholamine group, making them less susceptible to degradation by metabolic enzymes. They have increased oral bioavailability and lipophilicity, resulting in a longer duration of action. Their response is reduced by...
    Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

    Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

    β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...
    Drugs Affecting Neurotransmitter Synthesis01:29

    Drugs Affecting Neurotransmitter Synthesis

    Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase, which converts...
    Parkinson's Disease: Treatment01:24

    Parkinson's Disease: Treatment

    Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
    Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
    Antiasthma Drugs: Methylxanthines01:24

    Antiasthma Drugs: Methylxanthines

    Theophylline, a member of the methylxanthine class of bronchodilators, has long been used in asthma management. While its exact mechanism of action is not fully understood, it is believed to have multiple effects on various cellular processes.
    Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...
    Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists01:28

    Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists

    Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...